Net Income (Loss) Attributable to Parent in USD of Neuphoria Therapeutics Inc. from 2023 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Neuphoria Therapeutics Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from 2023 to Q3 2025.
  • Neuphoria Therapeutics Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$9,906,504.000, a 1131% decline year-over-year.
  • Neuphoria Therapeutics Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$9,501,717.000, a 12.2% increase year-over-year.
  • Neuphoria Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2025 was -$400,000.000, a 97.4% increase from 2024.
  • Neuphoria Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$15,492,166.000, a 27.5% increase from 2023.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Neuphoria Therapeutics Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$9,501,717 -$9,906,504 -$9,101,717 -11.3% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$400,000 -$8,914,025 -$6,226,999 -2.3% 01 Apr 2025 30 Jun 2025 10-Q 14 Nov 2025
Q1 2025 $5,826,999 $11,262,161 +$14,040,309 01 Jan 2025 31 Mar 2025 10-Q 20 May 2025
Q4 2024 -$8,213,310 -$1,943,349 +$2,611,075 +57.3% 01 Oct 2024 31 Dec 2024 10-Q 20 May 2025
Q3 2024 -$10,824,385 -$804,787 +$4,667,781 +85.3% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$15,492,166 -$2,687,026 01 Apr 2024 30 Jun 2024 10-K 29 Sep 2025
Q1 2024 -$2,778,148 01 Jan 2024 31 Mar 2024 10-Q 20 May 2025
Q4 2023 -$4,554,424 01 Oct 2023 31 Dec 2023 10-Q 20 May 2025
Q3 2023 -$5,472,568 01 Jul 2023 30 Sep 2023 10-Q 20 May 2025

Neuphoria Therapeutics Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2025 -$400,000 +$15,092,166 +97.4% 01 Jul 2024 30 Jun 2025 10-Q 14 Nov 2025
2024 -$15,492,166 +$5,889,511 +27.5% 01 Jul 2023 30 Jun 2024 10-K 29 Sep 2025
2023 -$21,381,677 01 Jul 2022 30 Jun 2023 10-K 30 Sep 2024
* An asterisk sign (*) next to the value indicates that the value is likely invalid.